CMS gives thumbs-up to PET/Alzheimer’s coverage
This article was originally published in The Gray Sheet
Final decision memo aligns with draft decision to cover the scans in a practical clinical trial and for differentiating between Alzheimer's disease and fronto-temporal dementia in patients that have been evaluated for other causes of dementia and still have uncertain clinical symptoms (1"The Gray Sheet" June 24, 2004, p. 6). The national coverage decision is the first reviewed under Medicare Modernization Act requirements for a draft decision posting followed by a 30-day comment period, and implementation of a final policy within 90 days of posting a final decision memo...
You may also be interested in...
CMS' decision to provide national coverage of FDG-PET imaging for some suspected dementia patients corresponds with the Neuroimaging Work Group of the Alzheimer's Association's consensus position
The EU’s massive economic stimulus package, Next Generation EU, includes a wide-ranging health program that aims to make health systems more resilient to future threats by supporting the development and manufacture of affordable new medicines and vaccines as well as measures to prevent drug shortages.
The Swiss major focused almost exclusively on the benefits of the combination of Tecentriq and its TIGIT inhibitor tiragolumab at ASCO but also celebrated the approval of a Tecentriq/Avastin combo for hepatocellular carcinoma.